Search

Leaders in Personalized Precision Medicine

Current Active Cancer Clinical Trials 

Active Clinical Trials - Dr. Von Hoff

For additional information about Cancer Clinical Trials at the Virginia G. Piper Cancer Center please contact the Clinical Trial Patient Care Coordinator at 480-323-1339 (toll free: 1-877-273-3713), or e-mail clinicaltrials@shc.org.

Find active Clinical Trials such as Solid Tumors click on a letter below:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


A

ADRENALCORTICAL CARCINOMA

  • A Phase 1 Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM-080301 in Patients with Advanced Solid Tumors

TOP OF PAGE


B

BASAL CELL CARCINOMA 

  • A Phase 1 Dose-escalation study of LY2940680 in patients with Advanced Cancer

BLADDER

  • A Phase 1 Study of Oral Azacitidine as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors

BRCA1 OR BRCA2 POSITIVE TUMORS

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors

BREAST CANCER 

  • An open-label, Phase 1, Dose-Escalation Study evaluating the safety and tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Tumors.
  • A Phase 3, Open Label, Randomized, Parallel, 2-arm, Multi-center study of BMN-673 versus physician’s choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer, who have received no more than 2 prior chemotherapy regimens for metastatic disease.
  • A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects with Selected HER2 Positive Cancers

TOP OF PAGE


C

COLON

  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

TOP OF PAGE


E

ENDOMETRIAL

  • An open-label, Phase 1, Dose-Escalation Study evaluating the safety and tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Tumors.

TOP OF PAGE


F

FALLOPIAN TUBE

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors)

TOP OF PAGE


G

GASTRIC

  • A Multicenter Phase 1/1b open label dose escalation study of ABT-700 a monoclonal antibody in subjects with advanced solid tumors.
  • A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

TOP OF PAGE


H

HEAD AND NECK

  • A Phase 1 Study of Oral Azacitidine as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors (Must be HPV positive)

 TOP OF PAGE


L

LIVER

  • A Phase I, multicenter study of MRX34 given intravenously two times per week for three weeks, repeated every four weeks in patients with unresectable primary liver cancer or advanced or metastatic cancer with liver involvement.

LUNG - NSCLC

  • A Multicenter Phase 1/1b open label dose escalation study of ABT-700 a monoclonal antibody in subjects with advanced solid tumors
  • A Phase 1, Multicenter, Open-label, Dose-escalation study of LY2812176 given intravenously weekly in patients with Multiple Myeloma or Advanced Solid Tumors
  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

LUNG - SCL

  • A Phase 1/2, First in Human, Single arm, open label study of once a day, orally administered BMN 673 in patients with Advanced or Recurrent Tumors - BRCA POSITIVE

LYMPHOMA 

  • An Open Label Phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, maximum tolerated dose and bio-marker response after intravenous administration of weekly BAY 80-6946 to patients with advanced cancer.
  • A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas

TOP OF PAGE


M

MELANOMA - BRAF POSITIVE 

  • A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 in Subjects With Advanced Solid Tumors

TOP OF PAGE


N

NEUROENDOCRINE

  • A Phase 1 Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM-080301 in Patients with >TKM-080301 in Patients with Advanced Solid Tumors

NEUROENDOCRINE - PANCREAS

  • A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamins of Intravenous Infusion of VX15/2503 in Adult Patients with Advanced Solid Tumors

TOP OF PAGE


O

OVARIAN CANCER

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors
  • A Phase 1 Study of Oral Azacitidine as a Single Agent and in Combination with Carboplatin or ABI-007 in
  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

TOP OF PAGE


P

PANCREATIC CANCER 

  • A Phase 1b Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and nab-Paclitaxel in Subjects With Advanced Solid Tumors
  • A Phase IB/II Pilot Trial of Nab-Paclitaxel plus Cisplatin Plus Gemcitabine (NABPLAGEM) in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (website pending)
  • SEENA TRIAL - A Phase II Study of Induction and Consolidation and Maintenance approach for patient with Advanced Pancreatic Cancer  - PCRT 11-002
  • SU2C-005 - A Phase I/II pharmacodynamic study of hydroxychloroquine in combination with Gemcitabine/abraxane to inhibit autophagy in Pancreatic cancer.
  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

PERITONEAL

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors

PIGMENTED VILLO-NODULAR SYNOVITIS (PVNS)

  • A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology – all cohorts are closed to enrollment with the EXCEPTION of the PVNS cohort.

TOP OF PAGE


R

RECTAL

  • An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination with Capecitabine and Radiation in Subjects with Locally Advanced Rectal Cancer (LARC)

TOP OF PAGE


S

SARCOMA

  • A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamins of Intravenous Infusion of VX15/2503 in Adult Patients with Advanced Solid Tumors

SOLID TUMORS

  • A Multicenter Phase 1/1b open label dose escalation study of ABT-700 a monoclonal antibody in subjects with advanced solid tumors.
  • A Phase 1 Open-Label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of BAX69 in subject with malignant solid tumors
  • A Phase 1b trial of the combination of PI3(Phosphoinositol 3)-K inhibitor BAY 80-6946 and MEK(Mitogen-activated Protein Kinase) inhibitor BAY 86-9766 in subjects with advanced cancer.
  • An open-label, Phase 1, Dose-Escalation Study evaluating the safety and tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Tumors.
  • A Phase 1b Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and nab-Paclitaxel in Subjects With Advanced Solid Tumors
  • A Phase 1, Multicenter, Open-label, Dose-escalation study of LY2812176 given intravenously weekly in patients with Multiple Myeloma or Advanced Solid Tumors
  • A Phase 1 Dose-escalation study of LY2940680 in patients with Advanced Cancer
  • A Phase I, multicenter study of MRX34 given intravenously two times per week for three weeks, repeated every four weeks in patients with unresectable primary liver cancer or advanced or metastatic cancer with liver involvement.
  • A Phase I/II, Multi-center, open label, dose escalation trial of the safety and Pharmacokinetics of Intravenous PR610 given weekly in subjects with solid tumors
  • A Phase 1, Open-Label, Randomized, Crossover study evaluating the bioavailability of TAS-102 tablets relative to an oral solution containing equivalent amounts of FTD and TPI in Advanced Solid Tumors (excluding breast cancer) for which no standard therapy exists
  • A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas
  • A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486-TsOH as a Single Agent and in Combination with Gemcitabine and nab-Paclitaxel in Patients with Advanced Solid Tumors
  • A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) in Subjects with Advanced Solid Tumors
  • A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluation the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein with GLA-SE Adjuvant in Patients with Unresectable or Metastatic Cancer Expressing NY-ESO-1 Antigen 9.
  • A Phase 1 Escalation Study of VS-5584, A Dual PI3K/MTOR inhibitor, pt’s with Advanced Non-Hematologic Malignancies or Lymphoma
  • A Phase I Study of Folic Acid-Conjugate EC1456 in Patients with Advanced Solid Tumors

SOLID TUMORS AND LYMPHOMA

  • A Phase 1 Escalation Study of VS-5584, A Dual PI3K/MTOR inhibitor, pt’s with Advanced Non-Hematologic Malignancies or Lymphoma

TOP OF PAGE